What CARB-X funds
CARB-X welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines and other products to combat the most serious drug-resistant bacteria. Please read the information on these pages carefully before submitting your application. Applications must be submitted using the secure Apply Here link above on the right. The Apply Online link functions only during the application period for each round.
The scope of CARB-X funding is restricted to projects that target drug-resistant bacteria highlighted on the ‘Antibiotic Resistant Threats in the United States’ report published by the Centers for Disease Control and Prevention (CDC) in 2013 or the Priority Bacterial Pathogens list published by the World Health Organization (WHO) in 2017 – with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list.
CARB-X has announced four separate rounds of funding in 2019 for projects that are in scope as outlined below. Applications must be submitted during the period indicated.
- Funding Round 1: NON-TRADITIONAL Approaches – June 3, 2019 through June 10, 2019, 5 pm ET (NOW CLOSED)
- Funding Round 2: VACCINES and BIOTHERAPEUTICS – July 8, 2019, through July 15, 2019, 5 pm ET (NOW CLOSED)
- Funding Round 3: DIAGNOSTICS – August 12, 2019, through August 19, 2019, 5 pm ET
- Funding Round 4: DIRECT ACTING SMALL MOLECULES – November 12, 2019, through November 19, 2019, 5 pm ET
- Project development stages
Funding round 1 – NON-TRADITIONAL Approaches – NOW CLOSED
June 3, 2019, through June 10, 2019, 5 pm ET
Round 1 applicants with Non-traditional projects must submit an Expression of Interest (EOI) June 3, 2019, through June 10, 2019, 5 pm ET, to be considered for CARB-X funding. Only on-line applications will be considered. The scope of Round 1 is highly specific. Click here for details of the scope of Round 1. For Round 1, for those whose Expression of Interest is selected to advance, Short Forms will be due the first week of August and Long Forms in the first week of November. Precise dates will be communicated to those applicants selected to move forward in the process.
Funding round 2 – VACCINES and BIOTHERAPEUTICS – NOW CLOSED
July 8, 2019, through July 15, 2019, 5 pm ET
Round 2 applicants with Vaccine and Biotherapeutic projects must submit an Expression of Interest (EOI) July 8, 2019, through July 15, 2019, 5 pm ET, to be considered for CARB-X funding. Only on-line applications will be considered. The scope of Round 2 is highly specific. Click here for details of the scope of Round 2. For Round 2, for those whose Expression of Interest is selected to advance, Short Forms will be due in the the second week of September and Long Forms in the second week of January 2020. Precise dates will be communicated to those applicants selected to move forward in the process.
Funding round 3 – DIAGNOSTICS
August 12, 2019, through August 19, 2019, 5 pm ET
Round 3 applicants with Diagnostic projects must submit an Expression of Interest (EOI) August 12, 2019, through August 19, 2019, 5 pm ET, to be considered for CARB-X funding. Only on-line applications will be considered. The scope of Round 3 is highly specific. Click here for details of the scope of Round 3. For Round 3, for those whose Expression of Interest is selected to advance, Short Forms will be due in mid-October and Long Forms in mid-February 2020. Precise dates will be communicated to those applicants selected to move forward in the process.
Funding round 4 – DIRECT ACTING SMALL MOLECULES
November 12, 2019, through November 19, 2019, 5 pm ET
Round 4 applicants with Direct Acting Small Molecule projects must submit an Expression of Interest (EOI) November 12, 2019, through November 19, 2019, 5 pm ET, to be considered for CARB-X funding. Only on-line applications will be considered. The scope of Round 4 is highly specific. Click here for details of the scope of Round 4. For Round 4, for those whose Expression of Interest is selected to advance, Short Forms will be due in early February 2020 and Long Forms in mid-May 2020. Precise dates will be communicated to those applicants selected to move forward in the process.
Project development stages
Antibiotics, other therapeutics and vaccines, CARB-X funds projects from Hit-to-Lead into Phase 1, generally restricting CARB-X support for clinical evaluation to include Phase 1 single ascending dose/multiple ascending dose evaluations in healthy volunteers (and in certain situations, patients). For a description of the development phases in scope for antibiotics and therapeutics, please click here. A description of development phases in scope for vaccines and biotherapeutics is COMING SOON.
Diagnostics, CARB-X funds projects from Feasibility Demonstration to System Integration and Testing. For a description of the development phases in scope for diagnostics, please click here. (UPDATES COMING SOON)
Please note that the scope definitions will be refined prior to the opening of the specific round.
- Slides of CARB-X 2019 Funding Rounds that include information on the scope and application process, as well as CARB-X’s new cost-share provisions, as discussed in a May 16, 2019, webinar.
- For specific questions about the application process, scope of funding or contractual requirements, please contact carbxapp@bu.edu
